Literature DB >> 11356504

Psychosis: pathological activation of limbic thalamocortical circuits by psychomimetics and schizophrenia?

F R Sharp1, M Tomitaka, M Bernaudin, S Tomitaka.   

Abstract

Non-competitive NMDA receptor antagonists, such as phencyclidine, ketamine and MK801, produce psychosis in humans. These drugs also produce injury to cingulate-retrosplenial cortex in adult rodents that can be prevented by GABA-receptor agonists and antipsychotics such as haloperidol and clozapine. MK801 injections into anterior thalamus reproduce limbic cortex injury, and GABA-receptor agonist injections into anterior thalamus prevent injury produced by systemic MK801. Inhibition of NMDA receptors on GABAergic thalamic reticular nucleus neurons might activate thalamocortical 'injury' circuits in animals. Pathological activation of thalamocortical circuits might also mediate the psychosis produced by NMDA-receptor antagonists in humans, and might contribute to psychosis in schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11356504     DOI: 10.1016/s0166-2236(00)01817-8

Source DB:  PubMed          Journal:  Trends Neurosci        ISSN: 0166-2236            Impact factor:   13.837


  42 in total

Review 1.  Excitation, inhibition, local oscillations, or large-scale loops: what causes the symptoms of schizophrenia?

Authors:  John Lisman
Journal:  Curr Opin Neurobiol       Date:  2011-11-11       Impact factor: 6.627

Review 2.  NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development.

Authors:  John H Krystal; D Cyril D'Souza; Daniel Mathalon; Edward Perry; Aysenil Belger; Ralph Hoffman
Journal:  Psychopharmacology (Berl)       Date:  2003-09-02       Impact factor: 4.530

Review 3.  Toward a neurobiology of delusions.

Authors:  P R Corlett; J R Taylor; X-J Wang; P C Fletcher; J H Krystal
Journal:  Prog Neurobiol       Date:  2010-06-15       Impact factor: 11.685

Review 4.  Glutamatergic model psychoses: prediction error, learning, and inference.

Authors:  Philip R Corlett; Garry D Honey; John H Krystal; Paul C Fletcher
Journal:  Neuropsychopharmacology       Date:  2010-09-22       Impact factor: 7.853

Review 5.  GSK-3β activity and hyperdopamine-dependent behaviors.

Authors:  Yan-Chun Li; Wen-Jun Gao
Journal:  Neurosci Biobehav Rev       Date:  2010-08-18       Impact factor: 8.989

Review 6.  Glutamate-mediated excitotoxicity in schizophrenia: a review.

Authors:  Eric Plitman; Shinichiro Nakajima; Camilo de la Fuente-Sandoval; Philip Gerretsen; M Mallar Chakravarty; Jane Kobylianskii; Jun Ku Chung; Fernando Caravaggio; Yusuke Iwata; Gary Remington; Ariel Graff-Guerrero
Journal:  Eur Neuropsychopharmacol       Date:  2014-08-01       Impact factor: 4.600

Review 7.  Testing models of thalamic dysfunction in schizophrenia using neuroimaging.

Authors:  K Sim; T Cullen; D Ongur; S Heckers
Journal:  J Neural Transm (Vienna)       Date:  2005-10-27       Impact factor: 3.575

8.  Postweaning social isolation exacerbates neurotoxic effects of the NMDA receptor antagonist MK-801 in rats.

Authors:  Dragos Inta; Peter Renz; Juan M Lima-Ojeda; Christof Dormann; Peter Gass
Journal:  J Neural Transm (Vienna)       Date:  2013-06-05       Impact factor: 3.575

Review 9.  Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia.

Authors:  John E Lisman; Joseph T Coyle; Robert W Green; Daniel C Javitt; Francine M Benes; Stephan Heckers; Anthony A Grace
Journal:  Trends Neurosci       Date:  2008-04-07       Impact factor: 13.837

Review 10.  Activation of metabotropic glutamate receptors as a novel approach for the treatment of schizophrenia.

Authors:  P Jeffrey Conn; Craig W Lindsley; Carrie K Jones
Journal:  Trends Pharmacol Sci       Date:  2008-12-06       Impact factor: 14.819

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.